MedTrace Logo

Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery

NCT07147049 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-12-22

No results posted yet for this study

Summary

This is a multiple-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and pharmacokinetics (PK) parameter of HL-1186 tablet for moderate to severe acute pain after surgery.

Conditions

  • Moderate to Severe Acute Postoperative Pain

Interventions

DRUG

HL-1186

HL-1186 tablet for oral administration.

DRUG

HL-1186 placebo

HL-1186 placebo tablet for oral administration.

Sponsors & Collaborators

  • Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-08
Primary Completion
2025-12-31
Completion
2026-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07147049 on ClinicalTrials.gov